Your browser doesn't support javascript.
loading
HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status.
Weitsman, Gregory; Barber, Paul R; Nguyen, Lan K; Lawler, Katherine; Patel, Gargi; Woodman, Natalie; Kelleher, Muireann T; Pinder, Sarah E; Rowley, Mark; Ellis, Paul A; Purushotham, Anand D; Coolen, Anthonius C; Kholodenko, Boris N; Vojnovic, Borivoj; Gillett, Cheryl; Ng, Tony.
Afiliação
  • Weitsman G; Richard Dimbleby Department of Cancer Research, Randall Division and Division of Cancer Studies, King's College London, Guy's Medical School Campus, London, UK.
  • Barber PR; Department of Oncology, Cancer Research UK and Medical Research Council Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK.
  • Nguyen LK; Institute for Mathematical and Molecular Biomedicine, King's College London, Guy's Medical School Campus, London, UK.
  • Lawler K; Systems Biology Ireland, University College Dublin, Belfield, Dublin, Ireland.
  • Patel G; Department of Biochemistry and Molecular Biology, School of Biomedical Sciences and Biomedical Discovery Institute, Monash University, Melbourne, Australia.
  • Woodman N; Institute for Mathematical and Molecular Biomedicine, King's College London, Guy's Medical School Campus, London, UK.
  • Kelleher MT; Richard Dimbleby Department of Cancer Research, Randall Division and Division of Cancer Studies, King's College London, Guy's Medical School Campus, London, UK.
  • Pinder SE; Sussex Cancer Centre, Brighton and Sussex University Hospitals, Royal Sussex County Hospital, Brighton, UK.
  • Rowley M; Research Oncology, Division of Cancer Studies, King's College London, Guy's Hospital, Great Maze Pond, London, UK.
  • Ellis PA; Breakthrough Breast Cancer Research Unit, Department of Research Oncology, Guy's Hospital King's College London School of Medicine, London, UK.
  • Purushotham AD; Department of Medical Oncology, St George's Hospital NHS Foundation Trust, London, UK.
  • Coolen AC; Research Oncology, Division of Cancer Studies, King's College London, Guy's Hospital, Great Maze Pond, London, UK.
  • Kholodenko BN; Breakthrough Breast Cancer Research Unit, Department of Research Oncology, Guy's Hospital King's College London School of Medicine, London, UK.
  • Vojnovic B; Institute for Mathematical and Molecular Biomedicine, King's College London, Guy's Medical School Campus, London, UK.
  • Gillett C; Research Oncology, Division of Cancer Studies, King's College London, Guy's Hospital, Great Maze Pond, London, UK.
  • Ng T; Research Oncology, Division of Cancer Studies, King's College London, Guy's Hospital, Great Maze Pond, London, UK.
Oncotarget ; 7(32): 51012-51026, 2016 Aug 09.
Article em En | MEDLINE | ID: mdl-27618787
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Biomarcadores Tumorais / Receptor ErbB-2 / Receptor ErbB-3 / Transferência Ressonante de Energia de Fluorescência / Microscopia de Fluorescência Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Biomarcadores Tumorais / Receptor ErbB-2 / Receptor ErbB-3 / Transferência Ressonante de Energia de Fluorescência / Microscopia de Fluorescência Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article